Enter assignee name

Forward Citations = 0

Loading Chart...

12 inventors (with patents filed for the assignee):

Zaiqi Wang (8 out of 8 patents)

Jiangwei Zhang (5 out of 5 patents)

Jun Jiang (4 out of 48 patents)

4. Baoyuan Zhang (3 out of 3 patents)

5. Jing Gao (1 out of 6 patents)

6. Yingxia Sang (1 out of 9 patents)

7. Shuang Xie (1 out of 3 patents)

8. Lihu Yang (1 out of 1 patent)

9. Ran Pang (1 out of 2 patents)

10. Xuebin Liu (1 out of 1 patent)

11. Ping Zhang (1 out of 1 patent)

12. Jiaming Gao (1 out of 1 patent)

8 patents: Sort by Forward Citations

1. 12257251 - Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation (2025-03-25),

2. 12121519 - Use of BI853520 in cancer treatment (2024-10-22),

3. 12115160 - Combined use of IN10018 and PLD (2024-10-15),

4. 12097200 - Combination of BI853520 with chemotherapeutic drugs (2024-09-24),

5. 12059421 - Use of BI853520 in cancer treatment (2024-08-13),

6. 11999719 - Solid form of compound (2024-06-04),

7. 11986477 - Drug combination and use for treating tumors (2024-05-21),

8. 11440916 - Selective A2A receptor antagonist (2022-09-13),

Inxmed (Nanjing) Co., Ltd. is a leading pharmaceutical company specializing in developing, manufacturing, and marketing innovative medical products. With a focus on research and development, Inxmed is committed to providing high-quality healthcare solutions to improve patient outcomes. The company's product portfolio includes a wide range of pharmaceuticals and medical devices to address various medical needs. Inxmed is dedicated to meeting the healthcare challenges of today and tomorrow through continuous innovation and excellence in the industry.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

8 Patents

#49 in Nanjing

#3,050 in China

Nanjing, China

Inxmed (nanjing) Co., Ltd.